Nuclear hormone receptors (NHRs) are major regulators of hormone-responsive breast and prostate cancers, and they function as targets for endocrine therapies and as biomarkers having very significant prognostic and predictive values. The overall goal of this project is to advance positron emission tomographic (PET) imaging of specific nuclear hormone receptors and receptor function to improve the management and treatment of breast and prostate cancer patients. While some PET imaging agents have been developed by us for the estrogen receptor (ER) and the androgen receptor (AR), the current status of PET imaging of NHR levels and function in breast and prostate cancer is rather underdeveloped, and many opportunities lie ahead. Our current aims are to: (1) Develop a Progesterone Receptor (PR) PET imaging hormone-challenge test to improve prediction of success of endocrine therapy in breast Cancer. Two PR PET imaging agents, the [18F]FFNP and [18F]FPTP will be studied in xenografts and murine mammary tumor models of ER-positive endocrine-sensitive and endocrine-resistant breast cancer. Hormone treatment protocols will be developed to optimize a 1-day estradiol challenge test for ER function, based on an acute change in PR-PET, to obtain a rapid, accurate and robust prediction of breast cancer hormone responsiveness. (2) Evaluate Fluorine-18 labeled ligands for the Peroxisome Proliferator-Activated Receptor gamma (PPAR?) as PET imaging agents of predictive value for prostate cancer recurrence. PPAR? levels measured by IHC in a nested case-control human prostate cancer tissue array resource will be examined for their predictive power for risk of recurrence. The uptake efficiency and selectivity of two F-18 labeled PPAR? ligands will be studied in preclinical models of prostate cancer to develop PPAR? PET imaging protocols for suspected primary prostate cancer that can distinguish aggressive from indolent disease and improve prediction of the risk of disease recurrence. (3) Design PET imaging agents for the Estrogen Related Receptor alpha (ERR?) to develop a novel ERR? PET-Imaging test of prognostic and predictive value in hormone-responsive and unresponsive breast cancer. Fluorine-substituted analogs of high affinity ERR? ligands will be prepared and labeled with fluorine-18 rapidly, at high specific activity. Their biodistribution will then be evaluated in preclinical models of ERR?-positive breast cancers to develop ERR? as a predictive marker for novel therapies for both ER-positive and negative breast cancers.

Public Health Relevance

The choice of appropriate endocrine therapies for breast and prostate cancer can be difficult;significant time can be lost when ineffective therapies are used and major morbidity can result from excessive treatments. PET imaging agents will be developed to measure important biomarkers in these two cancers by non-invasive imaging. The successful development, evaluation, and translation of these PET biomarker imaging agents to the clinic should significantly improve the management and care of breast and prostate cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA025836-33
Application #
8503375
Study Section
Clinical Molecular Imaging and Probe Development (CMIP)
Program Officer
Menkens, Anne E
Project Start
1984-01-01
Project End
2018-05-31
Budget Start
2013-06-18
Budget End
2014-05-31
Support Year
33
Fiscal Year
2013
Total Cost
$442,496
Indirect Cost
$139,055
Name
University of Illinois Urbana-Champaign
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
041544081
City
Champaign
State
IL
Country
United States
Zip Code
61820
Fowler, Amy M; Clark, Amy S; Katzenellenbogen, John A et al. (2016) Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer. J Nucl Med 57 Suppl 1:75S-80S
Paterni, Ilaria; Bertini, Simone; Granchi, Carlotta et al. (2015) Highly selective salicylketoxime-based estrogen receptor β agonists display antiproliferative activities in a glioma model. J Med Chem 58:1184-94
Zhou, Dong; Chu, Wenhua; Peng, Xin et al. (2015) Facile purification and click labeling with 2-[(18)F]fluoroethyl azide using solid phase extraction cartridges. Tetrahedron Lett 56:952-954
Chan, Szeman Ruby; Fowler, Amy M; Allen, Julie A et al. (2015) Longitudinal noninvasive imaging of progesterone receptor as a predictive biomarker of tumor responsiveness to estrogen deprivation therapy. Clin Cancer Res 21:1063-70
Bosch, Ana; Li, Zhiqiang; Bergamaschi, Anna et al. (2015) PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med 7:283ra51
Yasui, Norio; Mayne, Christopher G; Katzenellenbogen, John A (2015) Preparation of o-Fluorophenols from Nonaromatic Precursors: Mechanistic Considerations for Adaptation to Fluorine-18 Radiolabeling. Org Lett 17:5540-3
Zhou, Dong; Lin, Mai; Yasui, Norio et al. (2014) Optimization of the preparation of fluorine-18-labeled steroid receptor ligands 16alpha-[18F]fluoroestradiol (FES), [18F]fluoro furanyl norprogesterone (FFNP), and 16beta-[18F]fluoro-5alpha-dihydrotestosterone (FDHT) as radiopharmaceuticals. J Labelled Comp Radiopharm 57:371-7
Paterni, Ilaria; Granchi, Carlotta; Katzenellenbogen, John A et al. (2014) Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential. Steroids 90:13-29
Lee, Jae Hak; Peters, Olaf; Lehmann, Lutz et al. (2012) Synthesis and biological evaluation of two agents for imaging estrogen receptor ýý by positron emission tomography: challenges in PET imaging of a low abundance target. Nucl Med Biol 39:1105-16
Fowler, Amy M; Chan, Szeman Ruby; Sharp, Terry L et al. (2012) Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer. J Nucl Med 53:1119-26

Showing the most recent 10 out of 62 publications